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Abstract
Aims To explore the effectiveness of the Norfolk QOL-DN (QOL-DN), PN-QOL-97, and
NeuroQOL-28 as tools for early detection of diabetic peripheral neuropathy in overweight, obese,
and inactive (OOI), prediabetes (PD), and type 2 diabetes (T2D) individuals.
Methods Thirty-four adults were divided by A1C [(10 OOI, 13 PD, and 11 T2D] and the sural
nerves were tested bilaterally via NC-Stat DPN Check, conducting a sural nerve conduction study
(NCS). Participants were individually timed, filling out questionnaires (QOL-DN, NeuroQOL-28,
and PN-QOL-97) at a self-selected pace. Data were analyzed and compared to NCS findings to
determine the best instrument for early neuropathy detection, usability in screening settings, and
application for individuals with OOI, PD, and T2D.
Results Abnormal NCS results were obtained from 27 individuals, of which 25 were bilateral and
symmetrical. Confirmed DSPN criteria were met for 24, and 1 case met criteria for subclinical
neuropathy. Normal NCS findings, reported symptoms, and reduced bilateral sensation were found
in 7 cases. The QOL-DN and NeuroQOL-28 significantly predict neuropathy criteria in OOI, PD,
and T2D subjects. Analyses revealed the QOL-DN as the quickest for completion (M=5.17;
SD=1.83), followed by the NeuroQOL-28 (M=5.58; SD=3.56), and the PN-QOL-97 (M=13.23;
SD=3.606).
Conclusions The QOL-DN and NeuroQOL-28 are valid early screening measures for DPN
detection. Time completion studies revealed that the QOL-DN and NeuroQOL-28 may be used as
excellent short screening measures, completed in approximately 6 minutes or less, with reasonable
scoring for both. The NeuroQOL-28 is a better fit for immediate feedback, time constraints, or
limited staff. Future investigations should evaluate these tools for detection in DPN-prone
individuals and in subclinical populations screenings.
Keywords: Quality of Life; QOL-DN; PN-QOL-97; NeuroQOL-28; Overweight Obese Inactive

1. Introduction
Diabetes can be an overwhelming chronic
disease that places significant physical and
mental demands on individuals, often leading
to distress and degradation of consistent selfcare behaviors 1,2,3. Such stressors and
inconsistent monitoring behaviors may lead
to physical damage and health complications
caused by extended or acute hyperglycemia 4.
Hyperglycemia
promotes
early
microvascular complications related to
Copyright 2021 KEI Journals. All Rights Reserved

diabetic neuropathy (DN), including altered
eyesight, kidney damage, and impaired
psychosocial functioning, all of which may
bring significant health impacts 5, 6. Recently,
the International Prevalence and Treatment
of Diabetes and Depression Study
(INTERPRET-DD) was undertaken in 14
countries and found that among 2,733
participant aged 18–65 years with type 2
diabetes (T2D), the overall prevalence of
diabetic peripheral neuropathy 1 was 26.71%
https://esmed.org/MRA/mra/
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(95% CI: 25.08–28.40), emphasizing that this
health issue is commonplace in this
population 7, 8.
An individual’s outlook on life, how he or she
experiences it, interacts with others, and
chooses activities may be affected by a DN
diagnosis and individual symptomology.
Such adverse outcomes on an individual, the
ability to perform tasks, and psychosocial
functioning is referred to as health-related
quality of life (HRQOL) 9. HRQOL is an
important concept within diabetes care
management, particularly due to the rising
impact of the disease itself. Globally, as of
2019, more than 463 million people (9.3% of
the world’s population) were living with
some type of diabetes, and the International
Diabetes Federation estimates that number
will rise to 10.2% (578 million) by 2030 and
10.9% (700 million) by 2045 10, 11, and as
many as half of these individuals currently
with diabetes have not been diagnosed.
Research over the past several decades has
made great strides in developing several
HRQOL assessments that specialize in
assessing DN-related measures and address
HRQOL as a significant factor 12-15. Within
the realm of HRQOL, DN has been of
particular
interest,
with
individuals
dedicating significant research effort to the
validation of neuropathy-specific measures.
Individuals at risk for or who are
experiencing DN should be promptly
screened to facilitate optimal health
outcomes 16.
Diabetic neuropathy is the most common
chronic complication experienced in T2D 17
with over half of those with diabetes
experiencing neuropathy and diabetic
peripheral neuropathy 1,18. This complication
mimics other conditions and it is therefore
diagnosed by a process of excluding other
factors 4. Individuals with prediabetes (PD)

Copyright 2021 KEI Journals. All Rights Reserved
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have been found to have abnormal nerve
conduction study (NCS) results 19, raising
questions as to when DN develops 16, 20 and
how soon it affects QOL. Various types of
diabetic neuropathy may be experienced, but
generally fall into four areas including
peripheral, autonomic, proximal, and focal
neuropathies 4. Within these types of diabetic
neuropathies, the term distal symmetric poly
neuropathy (DSPN) is extremely common,
and attributable to ongoing micro vessel
damage from recurring hyperglycemia 21.
Furthermore, current research indicates that
having overweight, obese, or inactive status
19, 22
places an individual at increased risk for
disease, including potential progression to
PD and T2D and other forms of physiological
dysfunction, yet sparse research is available
relating to how these individuals may
experience DN 23. Neuropathy screening is
considered a standard of care for individuals
diagnosed with T2D, but not for overweight,
obese and inactive (OOI) individuals.
Therefore, the purpose of this study was to
compare three measures of QOL, the NQOL–
DN, the PN-QOL-97, and the NeuroQOL-28,
in adults with OOI, PD, and T2D to
determine which instrument may be the most
effective at detecting DPN at various stages
compared to a criteria standard, the NC–Stat
DPN Check (NeuroMetrix, Waltham, MA).
2. Subjects
This study included a total of 34 adults of
both sexes and varying ethnicities, divided
into three groups: 10 overweight, obese, and
inactive normoglycemic (OOI) individuals
22 (6 females, 4 males; 59.6+13.0 years), 13
individuals with prediabetes (PD) (11
females, 2 males; 56.4+12.2 years), and 11
individuals with T2D (7 females, 4 males;
59.6+12.1 years). Individuals with T1D,
active tobacco use, presence of hepatitis B,
hepatitis C, HIV, pregnancy, damage to the
lower extremities, history of nerve disease

https://esmed.org/MRA/mra/
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(other than neuropathy), history of peripheral
arterial disease, lower limb amputations, or
foot ulcers were excluded from participation.
Participants were recruited by flyers, email,
word
of
mouth
and
university
announcements. Subjects were screened by
phone for exclusionary factors prior to
reporting for testing. This research was
approved by the University Institutional
Research Board of Old Dominion University
and subjects participated in informed, signed
consent procedures before participating.
3. Materials and Methods
3.1 Procedures
Questionnaires were filled out after
individuals were screened and consented into
the study and prior to other data collection
measures. Completion times were tracked for
each instrument, allowing a comparison of
the time investment needed to utilize each
chosen method. Individuals were placed in a
quiet room with a volunteer research assistant
who timed their completion of each
instrument in minutes and seconds.
Questionnaires were checked by volunteer
research assistants and investigators for
completeness before proceeding to A1C
testing. Incomplete questionnaires were
completed before proceeding with the study.
3.2 Quality of Life Instruments
Norfolk Quality of Life Diabetic
Neuropathy Tool. The Norfolk Quality-of
Life Diabetic Neuropathy tool (QOL-DN)
has been found to be reliable across many
24-26
different
populations
.
This
comprehensive tool has demonstrated
sensitivity to both small and large fiber
impairment
while
also
detecting
24-26
improvements in neuropathy.
.
PN-QOL-97. This instrument has been
identified as a validated measure for
identifying DPN and successfully used in

Copyright 2021 KEI Journals. All Rights Reserved
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research 14, 27, 28. It is a PN-specific HRQOL
measure offering multiple psychometric
properties to be considered 13, 14.
NeuroQOL-28.
The
NeuroQOL-28
questionnaire instrument has been validated
as a neuropathy and foot ulcer specific QOL
tool, and subsequently utilized in a myriad of
studies evaluating key QOL factors involved
in the DPN experience 15, 29.
3.3 A1C Testing and Subject
Categorization
Sterile techniques were used to collect blood
samples and perform A1C testing.
Hemoglobin A1C (A1C) fingerstick testing
was performed with a Siemens DCA Vantage
2000 Analyzer 30 and DCA Vantage A1C test
kits following standardized protocols from
Lenters-Westra and Slingerland 30 and Selvin
et al. 31. Individuals were instructed prior to
their appointment to drink several glasses of
water within 2–3 hours before arriving for the
study to avoid errors on the test, such as high
total hemoglobin errors. Individuals were
also instructed to stay well hydrated for the
24-hour period beforehand. Assignment to
groups was based on current A1C testing
values obtained onsite during study
procedures, and subjects were categorized as
follows: OOI: 4.0–5.6%, PD: 5.7–6.4%,
T2D: 6.5% and above 31-33.
3.4 NC-Stat DPN Check
NC-Stat
DPN
Check
(DPN-Check,
NeuroMetrix Inc., Waltham, MA) procedures
followed previously outlined methods as
performed by Lee et al. 34. The point of care
device (POCD) test method involved a
bilateral examination of the lower extremities
to obtain sural nerve amplitude potential
(SNAP) and conduction velocity (SNCV) 34,
35
. The device allows for these evaluations by
nonclinical personnel assisting in DPN
detection at a significantly earlier stage when
compared to bedside tests 36-39. The unit

https://esmed.org/MRA/mra/
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utilized biosensor technology paired with 2
probes applied directly to the skin posterior
to the lateral malleolus. A single press of a
button distributed 100 mA of current, which
was detected by a single-use disposable
biosensor. A built-in thermometer accounted
for variances in temperature between 23oC
and 30oC and notified the operator if skin
temperatures were too cold for testing. SNCV
and SNAP values were attempted for each leg
with up to 5 attempts to collect the trials.
Device errors were not recorded; however,
zero readings were recorded by hand and reattempts we made up to the 5-trial limit, as
individuals permitted. The validity and
effectiveness of the NC-Stat DPN Check
system has been confirmed in prior research
35, 37
. This test served as a criterion standard
for the study and all other testing was
compared to this measure.
3.5 Data Analyses
Questionnaires were considered valid if
complete biographic information, including
age and sex was provided 40. Summary
statistics, in the form of continuous data is
presented with means and standard
deviations. Pertinent Spearman’s partial
correlations are presented. NC-Stat DPN
Check, measuring (3 trials) the right sided
sural nerve amplitude potential (RSNAP)
served as the comparable criterion standard,
determining confirmed distal symmetric
polyneuropathy (DSPN) or subclinical
DSPN.
Multiple regressions were run to attempt to
predict the right SNAP criterion through
modeling accounting for A1C, age, body
mass index, and selected correlated predictor
variables
from
each
questionnaire.
Comparisons involved running separate
multiple regression analyses with limited

Copyright 2021 KEI Journals. All Rights Reserved
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covariate and predictor variables with the aim
to predict DPN. Covariates and predictors
were entered at once, including accounting
for known factors such as A1C, age, and BMI
as a substitute measure for weight and height,
in order to best preserve the regression model
degrees of freedom (DOF) 41. Selected
neuropathy-related components were entered
into regression models based on potential
relationships presented in Spearman’s partial
correlations with appropriate choices
meeting the assumptions of regression,
avoiding
multicollinearity.
Linearity,
homoscedasticity,
independence
of
observations (research design and DurbinWatson), linear relationships, outliers (+3
SD), influential leverage cases, and multicollinearity
components
(correlations,
tolerance, variance inflation factor values)
were evaluated and addressed for each model
independently. All analyses were performed
using SPSS Version 22.0 and significance
was set at the p<0.05 level.
4. Results
4.1 Population Characteristics
Our population included 10 males and 24
females of Caucasian (64.7%) and African
American (35.3%) ethnicity, with A1C
ranges from 4.4–14.0% for all subjects
(Table 1). Fifteen of 34 individuals reported
no prior diagnosis or knowledge of T2D, or
PD. Five of 15 individuals had PD A1C
values and were grouped accordingly. A total
of 33 out of 34 individuals were overweight
or obese. Twenty-eight individuals reported
having no prior neuropathy diagnosis or
knowledge. Medication usage varied, with 10
of 34 participants reporting T2D specific
medication usage as part of their personal
medical plan. Two individuals with T2D
reported a combination of T2D and
neuropathy medication.

https://esmed.org/MRA/mra/
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4.2 Sural Nerve Conduction Amplitude
and Velocity Results
Overall group means for SNAP and SNCV
characteristics did not significantly vary by
A1C level (Table 2). Kruskal-Wallis-H
testing revealed no significant differences
among OOI, PD and T2D groups for SNAP
and SNCV values (SNAP: R, H(2)=1.460,
p=0.482; L, H(2)=2.369, p=0.30; SNCV: R,
H(2)=1.874, p=0.392, L, H(2)=1.880,
p=0.39). Raw data means and standard
deviations are presented. Twenty-seven

individuals
obtained
confirmed,
individualized, abnormal NCS results, of
which 25 were bilateral and symmetrical
(Table 3). Twenty-four participants presented
with combinations of abnormal distal signs
bilaterally, meeting criteria for confirmed
DSPN, and one case presented with no signs
or symptoms, indicating the presence of
subclinical neuropathy. Seven cases
presented with normal NCS findings, but in
the presence reported symptoms and reduced
bilateral distal sensation.

Table 1: NCS Results by Group
NC-Stat DPN Check - Sural Nerve
N
Min
Max
Mean
SNAP-R (μV)
OOI
10
2.0
14.3
6.631
PD
13
2.0
24.7
7.691
T2D
11
2.0
25.0
9.875
SNAP-L (μV)
OOI
10
2.3
21.7
7.129
PD
13
3.0
21.7
7.277
T2D
11
3.0
21.7
10.572
SNCV-R (μV)
OOI
10
35.3
55.7
46.2
PD
13
30.0
57.0
48.2
T2D
11
35.3
57.0
45.5
SNCV-L (μV)
OOI
10
41.3
55.0
47.265
PD
13
43.0
55.0
49.637
T2D
11
37.3
57.0
46.876
*Displayed in untransformed form, as raw data

Copyright 2021 KEI Journals. All Rights Reserved
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Std. Err

Std. Dev

1.444
1.674
2.133

4.567
6.037
7.076

1.834
1.186
2.064

5.798
4.277
6.847

1.902
1.871
1.816

6.016
6.747
6.022

1.519
1.072
1.946

4.803
3.865
6.455

https://esmed.org/MRA/mra/
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Table 2: Sural NCS, Signs and Symptoms

Variable
Sural NCS
34

N=

Normal
Abnormal*

7
27

OOI
1
10

PD
3
9

Group
T2D
3
8

14
20

3
7

6
7

5
6

3
31

1
9

0
13

2
9

Total

Tuning Fork
Normal
Abnormal*
Monofilaments
Signs

N = 34

1-g
Normal
Abnormal*
10-g

Normal
3
1
0
Abnormal*
31
9
13
None
Reported
11
6
1
Symptoms N =
34
Reported**
23
4
12
None Reported
21
7
8
Autonomic N
=34
Reported**
13
3
5
None Reported
26
8
10
ADLS
N = 34
Reported**
8
2
3
AbNCS, Signs &
17
3
9
Symptoms
AbNCS, Signs or
9
5
1
NCS, Sign &
Symptoms
Symptom
AbNCS, No Signs or
Combinations
1
1
0
Symptoms
NNCS, Signs &
7
1
3
Symptoms
*Bilateral testing; abnormal findings on at least one limb; **Self-reported on QOL-DN
AbNCS = Abnormal nerve conduction study; NNCS = Normal nerve conduction study

Copyright 2021 KEI Journals. All Rights Reserved

2
9
4
7
6
5
8
3
5
3
0
3
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Table 3: Spearman Partial Correlations
RSNAP
LSNAP
QOL-DN
N=34
N=34
Corr.
-0.289
-0.352
Total Score
Sig.
0.128
0.061
Corr.
-0.275
-0.322
Large Fiber
Sig.
0.149
0.088
Corr.
-0.251
-0.185
Small Fiber
Sig.
0.189
0.336
Corr.
-0.291
*-0.417
Symptoms
Sig.
0.126
0.024
Corr.
-0.331
-0.260
ADLS
Sig.
0.079
0.164
Corr.
-0.188
-0.297
Autonomic
Sig.
0.328
0.117
PN-QOL-97
N=34
N=34
Corr.
0.350
*0.399
Physical
Sig.
0.063
0.032
Corr.
*0.505
*0.479
Mental
Sig.
0.005
0.009
NeuroQOL-28
N=34
N=34
Corr.
-0.194
-0.334
Total Score
Sig.
0.314
0.077
Corr.
-0.305
*-0.464
Neuropathy Specific
Sig.
0.108
0.011
Corr.
*0.523
*0.426
Overall QOL Judgement
Sig.
0.004
0.021
All correlations account for HbA1C, age, height, and weight.
* significance at the 0.05 level
4.3 Correlations
Spearman’s partial correlations were run
between NC-Stat DPN Check criteria
standard variables, which were the right and
left SNAP and SNCV values, and all
questionnaire data components while
accounting for age and A1C values.
Significant correlations were identified and
are presented in Table 4. The QOL-DN
symptom component moderately correlated
with the right SNAP criterion [R, rs(34)=0.365, p=0.044]. The PN-QOL-97 physical
component score moderately correlated with
both the right and left SNAP criteria [R,

Copyright 2021 KEI Journals. All Rights Reserved

RSNCV
N=34
-0.004
0.985
-0.058
0.765
-0.340
0.071
0.047
0.808
0.066
0.734
-0.091
0.638
N=34
0.107
0.579
0.052
0.791
N=34
-0.288
0.129
-0.177
0.358
0.194
0.312

LSNCV
N=34
-0.242
0.205
-0.290
0.127
-0.361
0.054
-0.102
0.597
-0.074
0.701
-0.188
0.329
N=34
0.166
0.389
-0.101
0.603
N=34
-0.279
0.142
-0.204
0.287
0.025
0.897

rs(34)=0.375, p=0.038; L, rs(34)=0.366,
p=0.043], as did the mental component
scores; however, the relationship was
considerably stronger [R, rs(34)=0.522, p
=0.003;
L,
rs(34=0.451,
p=0.011].
NeuroQOL-28
neuropathy
specific
components moderately strongly correlated
to the left SNAP [rs(34)=-0.426, p=0.017],
and the NeuroQOL-28 overall QOL
judgment
score
strongly
[RSNAP,
rs(34)=0.541, p=0.002], and moderately
correlated [LSNAP, rs(34)=0.396, p=0.028]
to our criteria SNAP values.

https://esmed.org/MRA/mra/
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Table 4: Regression Results
Unstd. Coeff.

Constant
Age
A1C
BMI
Symptoms

28.084
-0.311
0.262
-0.11
3.613

Std.
Error
7.291
0.066
0.593
0.149
2.523

Total QOL

-2.719

1.096

QOL-DN Regression
Results

B

Std.
Coeff.

t

Sig.

95% Conf. Int for
B.

-0.629
0.069
-0.101
0.347

3.852
-4.738
0.441
-0.741
1.432

0.001
0
0.663
0.465
0.163

Lower
Bound
13.15
-0.446
-0.954
-0.416
-1.555

-0.55

-2.481

0.019

-4.964

-0.474

-0.73
0.374
-0.178
0.076
0.349

-1.08
-4.525
2.392
-1.326
0.384
1.874

0.29 -137.85
0 -0.507
0.025
0.362
0.197 -0.528
0.705 -19.529
0.073 -1.195

43.014
-0.19
4.853
0.114
28.47
25.399

0.99 -38.157
0 -0.494
0.106 -0.207
0.815 -0.273

37.688
-0.22
2.042
0.345

0.412 -18.545

7.829

Beta

Upper
Bound
43.018
-0.177
1.477
0.195
8.78

PN-QOL-97 Regression Results

Constant
Age
A1C
BMI
Physical Score
Mental Score

-47.42
-0.348
2.608
-0.207
4.47
12.102

43.91
0.077
1.09
0.156
11.653
6.456

NeuroQOL-28 Regression Results

Constant
Age
A1C
BMI
Neuropathy
Specific
Overall QOL
Judgement

-0.235
-0.357
0.918
0.036

18.513
0.067
0.549
0.151

-0.721
0.243
0.032

-0.013
-5.344
1.671
0.236

-5.358

6.438

-0.129

-0.832

15.748

6.18

0.422

2.548

4.4 Completion Times
Completion times analyses revealed that the
QOL-DN (M=5.17; SD=1.83) was the
quickest, on average to complete, followed
by the NeuroQOL-28 (M=5.58; SD=3.56)
and QOL-97 (M=13.23; SD=3.61).
4.5 Questionnaires
QOL-DN Questionnaire. A multiple
regression was run to attempt to predict the
right SNAP criterion with a regression model

Copyright 2021 KEI Journals. All Rights Reserved

0.017

3.089

28.406

that accounted for A1C, age, BMI, QOL-DN
Symptoms and Total QOL Scores as
predictors. The multiple regression model
significantly predicted the right SNAP value,
F(5,28)=6.118, p<0.001, adj. R2=0.52. Age
(p=0.000) and Total QOL (p=0.019)
significantly added to the prediction.
Regression coefficients and standard errors
for all three questionnaires are presented in
Table 5.
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Figure 1. Dual Y Axes with Categorical X Axis Mean of Norfolk Quality of Life Completion
Time, Mean of NeuroQOL Completion Time by A1C Numeric Value
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PN-QOL-97 Questionnaire. A multiple
regression was run to attempt to predict the
right SNAP criterion with a regression model
that accounted for A1C, age, BMI, and PNQOL-97 Physical and Mental Scores as
predictors. This model significantly predicted
the right SNAP value, F(5,25)=7.465,
p<0.0005, adj. R2=0.52. Age (p=0.000) and
A1C (p=0.025) significantly added to the
prediction.
NeuroQOL-28 Questionnaire. A multiple
regression was run to attempt to predict the
right SNAP criterion with a regression model
that accounted for A1C, age, BMI, the
NeuroQOL-28
Neuropathy
Specific
Component, and Overall QOL Judgment as
predictors. The multiple regression model
significantly predicted the right SNAP value,
F(5,28) =7.238, p<0.0005, adj. R2=0.49. Age
(p=0.000) and Overall QOL Judgment
(p=0.017) significantly added to the
prediction.
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5. Discussion
Although the QOL-DN, PN-QOL-97, and
NeuroQOL-28 have been validated for use in
research as neuropathy instruments to detect
DPN, further analysis of these instruments
has been recommended 12, 13 . We sought to
determine which of three instruments, the
QOL-DN 42, the PN-QOL-97, 14 or the
NeuroQOL-28 15 would be the best predictor
of neuropathy when compared to our criteria
standard measurements in OOI, PD, and T2D
populations. The QOL-DN Symptoms
component correlated with our LSNAP, but
not with the RSNAP, thus regression results
revealing a predictor relationship between the
Total QOL and RSNAP were not surprising.
Examination of bilateral results will be
reported elsewhere.
We had anticipated that the QOL-DN would
more clearly identify early, or subclinical PN
given that the instrument had previously
identified 6,000 cases of undisclosed
neuropathy amongst individuals with
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diabetes in a 25,000 person study in
Romania40. Our study provides support for
this finding through Total QOL-DN
(p=0.019) component scores of this
instrument. Our results indicate that the
QOL-DN, but not the PN-QOL-97, predicted
our criterion standard RSNAP value within
our regression models, although the PNQOL-97’s Mental Score was relatively close
to significance (p=0.073). The NeuroQOL28 Overall Judgment of QOL (p=0.017)
demonstrated significant predictive qualities
for early detection, giving further validation
to this short questionnaire, yet asymmetry
existed in its correlational relationship across
the RSNAP and LSNAP variables. Normal
variants within our target population could
account for such asymmetries. Twenty-six of
34 individuals had abnormal NCS. Of these
26 participants, 24 reported symptoms
(recorded via QOL-DN) and the presence of
bilateral symmetrical signs as evidenced by
1-g and 10-g monofilaments, 128-Hz tuning
fork, and reported symptoms, meeting the
requirements for confirmed DSPN 43.
In hypothesizing which instrument would be
most effective to detect DPN in our OOI, PD,
and T2D populations, we had predicted a
correlation of 0.60, or higher between these
tools and the NC-Stat DPN Check criteria
SNAP and SNCV values. However, our
results indicate that all three measures failed
to meet this level; although they correlated to
our criteria, the association was not as strong
as clinically desirable. Correlations revealed
significant relationships between the RSNAP
and the Neuropathy Overall Judgment QOL
(rs = 0.523), and PN-QOL-97 Mental Scores
(rs = 0.505) for the RSNAP, but not for the
QOL-DN.
Early detection is considered critical, yet is
difficult to accomplish with currently
available methods. Others emphasize the
importance of early DPN detection in their
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research, advising small fiber evaluation as to
catch the pathophysiological process in the
earliest stages 20, 41, 44. Clinical exams readily
identify small fiber pathology, often using
Neurotips (pain and warmth detection), or a
cold 128-Hz tuning fork (thermoreceptor
evaluation) 4. Large fiber neuropathy, which
is the primary focus of the NC-Stat DPN
Check tool, may also be evaluated through
hands-on measures (NC-Stat DPN-Check, 1g, 10-g monofilaments, 128-Hz tuning fork)
in clinical or on-site applications to test
pressure and large fiber sensitivity changes.
Small fiber dysfunction, however, is difficult
to detect, often requiring skin biopsy for
confirmed status, paired with abnormal QST
and clinical exams, requiring clinical
appointments. We emphasize the necessity of
easy-to-use screening tools that may be
utilized in short time commitment
community screening efforts. The oftensilent beginnings of small fiber dysfunction
do not readily lead individuals to seek the
clinical assessment necessary to catch the
pathology. Unless experiencing symptoms,
such as brief pins-and-needles, pricks, or
shock sensations, they have little to move
them towards clinical evaluation.
Previous research indicated strengths and
weaknesses for each instrument prior to the
execution of this study; however, it should be
noted that each instrument may be more
adept at differentiating different components
of fiber loss, meaning one may be more able
to detect small fiber, another identifies with
large fiber loss and another may do well with
both or detect autonomic components as well.
Our criteria focused on large fiber
measurement, and future study designs may
need to incorporate multiple means to assess
the effectiveness of these QOL tools, ones
that address small, large, and autonomic
neuropathy components, to better detect the
strengths of each instrument. This might
include simple bedside tests, such as a cold
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tuning fork and Neurotips, to evaluate small
fiber components.
The further development of questionnaires to
screen for small fiber component dysfunction
should be a priority as much of the public
does not seek medical attention until
symptoms have become obvious. Ultimately,
the focus of patient reported outcomes such
as the QOL-DN, PN-QOL-97, and the
NeuroQOL-28 is DPN screening and
detection, thus evaluating these instruments
for different facets of the targeted disease
population and determining each tool’s
viability in that subset was a useful objective
of the current study. Both the QOL-DN and
NeuroQOL-28
likely
identified
key
subjective measures that align well with
objective screening measure in early
hyperglycemic processes within our small
pilot population. The QOL-DN was
effectively employed to identify key
symptomology necessary for the diagnosis of
DPN, aiding and assisting in a patient
centered, cumulative approach. These
instruments are available in US and UK
versions, with the NeuroQOL-28 available in
10 languages and the QOL-DN available in 8
13
, indicating widespread availability for
research and screening efforts. Strengths of
the QOL-DN are highlighted by Vinik,
Hayes, Oglesby, Bastyr, Barlow, FordMolvik and Vinik 42, where the QOL-DN
demonstrates a well-rounded approach,
uncovering multiple neuropathy-related
components,
including
complications,
medication use, autonomic factors, fiber
specific domains, and validated use for
revealing undisclosed neuropathy 40, 42. Our
study showed similar results, disclosing DPN
in individuals who were unaware of their
deteriorating physiological state, revealing
promise for the QOL-DN in revealing disease
in diverse population settings. The
NeuroQOL-28 focuses on painful symptoms,
reduced sensation, ADLS, diffused sensory

Copyright 2021 KEI Journals. All Rights Reserved

Page 12 of 16

and motor changes, emotional changes, and
overall QOL, which likely explains its
usefulness in our study 15. These facets relate
to our research, as the completion of results
reflect a strong indication of neuropathy in
this population, suggesting that careful
screening of individuals at earlier stages may
be quite beneficial in the DPN detection
process, even prior to acute hyperglycemia
diagnosis. Elevated A1C status in such
populations is associated with the
development of decreased motor and sensory
nerve conduction velocities, which may arise
out of acute bouts of hyperglycemia
experienced though postprandial excursions
45, 46
. Our participants were likely to report a
variety of component changes, including
psychometric properties that are evaluated
and reported by this measure. Currently, each
questionnaire has its strengths and should be
applied accordingly.
Previous research has reported unknown
completion times for the NeuroQOL-28 and
QOL-DN 13, making this study the first to
document time to completion for all three
measures. Our finding that completion times
were shorter for the QOL-DN and
NeuroQOL-28 suggests that these two would
ultimately make better choices for optimizing
community
screening
efforts.
Both
instruments can be employed within a short
time, and the choice between which measure
to use in future early DPN investigations is a
difficult one as these instruments are
typically applied in populations that are
likely further along in their disease process
than the ones in this pilot work. Quickly
completed PROMs provide more leeway for
integration into community screenings, as
does quick scoring in order to be of
immediate use to the individual. Of the 3
measures, scoring is easiest for the
NeuroQOL-28, which can be done in less
than 5 minutes. The QOL-DN requires
additional time to provide feedback and
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likely, contact information or a second
reporting to disseminate results. The PNQOL-97
requires
elaborate
scoring
accomplished through Excel.
Limitations that should be considered include
that we performed a pilot study and
generalizations may not be made to large
populations. Lack of random assignment and
use of volunteers for subjects created
potential selection bias, with clinical
population research targeting and low
available funding heavily influencing this
method. The A1C machine that was used
within the study is a validated machine 30, but
oral glucose tolerance testing is preferred by
some research scientists, particularly for
individuals
with
cardiac
autonomic
neuropathy (CAN) 47, which we did not
screen for and, therefore, we cannot account
for unknown discrepancies. The NC-Stat
DPN Check device was used solely to test the
sural nerve; thus, deficits in nerve function
relating to other nerves of the lower leg were
not confirmed through this device. Previous
research has not investigated the validity of
the QOL-DN, PN-QOL-97, and the
NeuroQOL-28 within an OOI population and
this should be considered when interpreting
our findings. Furthermore, each of these
instruments detects particular types of
neuropathy, and we only assessed large fiber
components with our NC-Stat DPN check
device.
6. Conclusions
Both the QOL-DN and NeuroQOL-28
significantly predict neuropathy criterion
standard components in OOI, PD, and T2D
subjects, adding validity to their use as
screening measures as early DPN detection
tools. The PN-QOL-97 effectively identified
multiple DPN-related issues; however, its
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ability to predict our criteria standards were
not statistically significant. Time completion
studies revealed that the QOL-DN and
NeuroQOL-28 may be used as excellent short
screening
measures,
completed
in
approximately 6 minutes or less, with
reasonable scoring for both. The NeuroQOL28 is a better fit for immediate feedback, time
constraints or limited staff. Consideration
should be given to adding fiber specific
domains to the NeuroQOL-28 and
psychological measures assessing the impact
of depression to the QOL-DN, thus adding
potential to both instruments to align with
different facets potentially experienced by
the target population, hopefully increasing
the power of their constructs. Asymmetry in
NCS findings warrants proposing that future
research consider how falls and injuries may
contribute to the uneven pathogenesis of
SNAP values in subacute and acute
hyperglycemic populations and to further
explore other options for effective screening
for early DPN. Priority should be given to
investigations seeking to evaluate the
effectiveness of these tools to detect DPN
within early, DPN prone, predefined
populations, providing new opportunities to
increase the effectiveness of these and other
instruments in subclinical population
screening efforts.
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